Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Kohl's, Rivian and AMC Entertainment fall premarket; GM and Procter & Gamble rise

Published 01/03/2023, 14:12
Updated 01/03/2023, 14:12
© Reuters.

By Peter Nurse

Investing.com -- Stocks in focus in premarket trade on Wednesday, March 1st. Please refresh for updates.

  • Kohl's (NYSE:KSS) stock fell 7.3% after the department store chain reported a holiday-quarter loss and forecast full-year profit below expectations as customers tightened their spending.

  • Lowe’s (NYSE:LOW) stock rose 0.3% after the home improvement retailer beat quarterly profit expectations, but offered up a disappointing full-year sales forecast, as soaring prices cause consumers to pause spending on home-related projects.

  • Rivian (NASDAQ:RIVN) stock slumped 8.6% after the electric vehicle manufacturer forecast 2023 production well below estimates, and announced a recall of more than 12,700 vehicles.

  • Tesla (NASDAQ:TSLA) stock rose 0.4% ahead of an investor day, and with the electric car manufacturer set to confirm a new factory in Mexico after striking a water deal.

  • AMC Entertainment (NYSE:AMC) fell 6.9% after the cinema chain recorded a more than 15% fall in fourth-quarter revenue, adding that the box office is yet to return to pre-pandemic norms.

  • Novavax (NASDAQ:NVAX) stock slumped 27.8% after the drugmaker said there is significant uncertainty around its 2023 revenue and announced plans to slash spending ahead of the autumn vaccination campaign.

  • Dollar Tree (NASDAQ:DLTR) stock fell 3.2% after the discount chain forecast full-year profit below expectations as customers reined in discretionary spending.

  • Procter & Gamble (NYSE:PG) stock rose 1.3% after UBS upgraded its stance on the consumer goods giant to ‘buy’ from ‘neutral’, saying the shares can rally nearly 20% from current levels.

  • General Motors (NYSE:GM) stock rose 0.9% after the auto giant announced it was cutting hundreds of high-level jobs as it looks to cut costs and streamline operations.

  • Sarepta Therapeutics (NASDAQ:SRPT) stock rose 17.1% after Morgan Stanley upgraded its stance on the biotech to ‘overweight’ from ‘equal-weight’, saying its shares can rally more than 50%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.